BIOMAT Database Logo BIOMAT Database Logo

Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. 2011

Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

Based on rational drug design approach, a series of novel thiazolidin-4-ones bearing different aryl/heteroaryl moieties at position C-2 and N-3 are synthesized and evaluated as potent inhibitors for human immunodeficiency virus type-1 reverse transcriptase enzyme (HIV-1 RT). An in vitro HIV-1 RT assay showed that the compounds 4, 5, 6, 8, 12, 13, 14 and 17 have shown high inhibition of reverse transcriptase (75.41, 95.50, 98.07, 91.24, 85.27, 77.59, 84.11 & 76.49% inhibition) enzyme activity. Further, cell based assay showed that compounds 4, 5, 8 &12 are identified as the best compounds of the series (EC(50) ranged from 0.09 to 0.8 μg/ml and 0.12 to 1.06 μg/ml) against HIV-1 III(B) and HIV-1 ADA5 strains, respectively. Moreover, the compounds which were active against HIV-1 III(B) and HIV-1 ADA5 were also found to be active against primary isolates (EC(50) ranged from 0.10 to 1.55 μg/ml against HIV-1 UG070 and 0.07 to 1.1 μg/ml against HIV-1 VB59), respectively. Structure-activity relationship (SAR) studies demonstrated the importance of the lipophilic bulky substituent pattern on compact heteroaryl ring at N-3, replacement of C4' at C-2 phenyl by trivalent bioisosteric nitrogen and dihalo groups at C-2 aryl/heteroaryl of thiazolidin-4-ones is crucial for anti-HIV-1 activity. Molecular modeling of compounds 4, 5, 8 and 12 in complex with HIV-1 RT demonstrate that there is good correlation of results obtained from SAR studies. Therefore the compounds 4, 5, 8 and 12 may be considered as good candidates for further optimization of anti-HIV-1 activity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Novel Thiazolidin-4-ones as Potential Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase.
October 2019, Molecules (Basel, Switzerland),
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
August 2004, Antiviral research,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
June 2014, Bioorganic & medicinal chemistry,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
June 2010, ChemMedChem,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 2006, Bioorganic & medicinal chemistry letters,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
April 2012, Bioorganic & medicinal chemistry letters,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
August 2016, Bioorganic & medicinal chemistry letters,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Pyridin-2(1H)-ones: a promising class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
August 2007, ChemMedChem,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
February 2010, Bioorganic & medicinal chemistry,
Vanangamudi Murugesan, and Vinay S Tiwari, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Nandini Makwana, and Rahul Suryawanshi, and Seturam B Katti
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
November 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!